2 insiders at Lexicon Pharmaceuticals, Inc. (LXRX) reported open-market stock purchases totaling $2,722,625 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from Invus Global Management, LLC (director, 10 percent owner: ), who acquired 1,538,462 shares at $1.30 on February 02, 2026.
Source: SEC Form 4. Option grants and tax-withholding sales are excluded.
| Date | Insider | Role | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2026-02-25 | DEBBANE RAYMOND | director | 2,000 | $1.49 | $2,980 | SEC Form 4 |
| 2026-02-23 | DEBBANE RAYMOND | director | 100,000 | $1.47 | $147,000 | SEC Form 4 |
| 2026-02-20 | DEBBANE RAYMOND | director | 100,000 | $1.48 | $147,790 | SEC Form 4 |
| 2026-02-19 | DEBBANE RAYMOND | director | 50,000 | $1.44 | $71,965 | SEC Form 4 |
| 2026-02-18 | DEBBANE RAYMOND | director | 133,688 | $1.32 | $176,468 | SEC Form 4 |
| 2026-02-17 | DEBBANE RAYMOND | director | 76,857 | $1.31 | $100,544 | SEC Form 4 |
| 2026-02-13 | DEBBANE RAYMOND | director | 57,952 | $1.31 | $75,877 | SEC Form 4 |
| 2026-02-02 | Invus Global Management, LLC | director, 10 percent owner: | 1,538,462 | $1.30 | $2,000,001 | SEC Form 4 |
Lexicon Pharmaceuticals, Inc. is a Healthcare company in the Biotechnology industry. It carried a market capitalization of about $1.1B, with shares trading near $2.55.
This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.